Pipeline Icon

 

 
 

The products under development support our strategy of developing insulin delivery systems as part of a therapy management portfolio designed to improve patient outcomes, and include automated insulin delivery system enhancements, a next-generation hardware platform, and connected (mobile) health offerings.

 
 

Changing the face of insulin pump therapy

The information below discusses products that may not be approved by the FDA. This information is intended for investors researching the company, and is updated in conjunction with public announcements about our product pipeline. All dates and information below are as of April 30, 2020. Tandem undertakes no obligation to update or review any forward-looking information below based on new information, future events or other factors.

 
 

 
 

Next-Generation Platform: t:sport Insulin Delivery System

Our next-generation hardware platform is referred to under its development name, t:sport. The t:sport insulin pump is half the size of t:slim X2™ insulin pump and is being designed for people who seek even greater discretion and flexibility with the use of their insulin pump. We anticipate that t:sport will feature a 200-unit cartridge, an on-pump bolus button, a rechargeable battery, an AID algorithm, and a Bluetooth® radio. We are designing the product so that it will have the technical capability to be controlled using either a dedicated controller or our mobile device application.

 
 

 
 

Connected (Mobile) Health Offerings

We are preparing for the launch of a mobile application that has been designed to wirelessly upload pump data to our t:connect® web application, receive notification of pump alerts and alarms, and provide a discrete, secondary display of pump therapy data. Future updates of this app are expected to integrate other health-related information from third party sources and, subject to future regulatory approvals, support future pump-control capabilities for t:slim X2 pump and other products under development.